Clinical Trials Browser

Anemia, Refractory, with Excess of Blasts, Lymphoma, Lymphoma, Non-Hodgkin, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Neoplasms, Plasma Cell, Primary Myelofibrosis

NCT07410403 2026-02-13

AI

Enrolling by invitation

10 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04155749 2026-02-11

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

Phase 1 Active not recruiting

40 enrolled

Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT05651932 2026-02-10

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Phase 1 Recruiting

125 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT07390071 2026-02-05

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

Phase NA Recruiting

40 enrolled

LymphoidPlasma cell

Cytokine Release Syndrome, Lymphoma, Neoplasms, Plasma Cell

NCT06152575 2026-02-03

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Phase 3 Recruiting

492 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01208662 2026-01-22

DFCI 10-106

Phase 3 Active not recruiting

729 enrolled 29 charts

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06870760 2026-01-21

Pre-malignant States to Hematologic Malignancies in Firefighters

Recruiting

300 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Non-Hodgkin, Multiple Myeloma, Paraproteinemias, Neoplasms, Plasma Cell

NCT07354555 2026-01-21

MMExFFPE

Not yet recruiting

15 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04822337 2026-01-20

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

Phase 1/2 Recruiting

70 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05063591 2026-01-15

BRUOG-407

Phase NA Completed

18 enrolled 8 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT05625971 2026-01-07

NIRVANA

Completed

36 enrolled

Plasma cell

Neoplasm, Residual, Neoplasms, Plasma Cell

NCT01208766 2026-01-06

HO95

Phase 3 Completed

1,503 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03702725 2026-01-06

Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Phase 1 Completed

14 enrolled 15 charts

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05228470 2026-01-06

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Phase 2 Completed

39 enrolled 15 charts

LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT07319897 2026-01-06

A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma.

Phase 2/3 Not yet recruiting

300 enrolled

Plasma cell

Disease, Multiple Myeloma, Neoplasms, Plasma Cell

NCT04952766 2025-12-23

EREVA

Phase 4 Completed

196 enrolled

Other hematologic neoplasmPlasma cell

Acquired Immunodeficiency Syndrome, Diabetes Mellitus, Type 2, Hypergammaglobulinemia, Multiple Sclerosis, Neoplasms, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT00466674 2025-12-19

IFM 2005-03

Phase 2 Completed

13 enrolled

Plasma cell

Neoplasms, Plasma Cell

NCT05055063 2025-12-18

A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

Phase 1 Recruiting

30 enrolled

Plasma cell

Neoplasms, Plasma Cell

NCT04268199 2025-12-15

EASE

Phase 2 Recruiting

100 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04680468 2025-12-15

Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma

Phase 2 Active not recruiting

41 enrolled

Plasma cell

Neoplasms, Plasma Cell

NCT05182073 2025-12-12

FT576 in Subjects With Multiple Myeloma

Phase 1 Completed

31 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06518551 2025-12-11

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Phase 1/2 Recruiting

49 enrolled

Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT05065866 2025-12-04

Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

Phase 1 Completed

14 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Neoplasms, Plasma Cell

NCT05763563 2025-12-04

Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy

Phase NA Active not recruiting

20 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Neoplasms, Plasma Cell

NCT06947083 2025-12-03

Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma

Phase 2 Recruiting

39 enrolled

Plasma cell

Neoplasms, Plasma Cell

NCT04649359 2025-12-02

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

Phase 2 Active not recruiting

187 enrolled 14 charts 1 FDA

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01177527 2025-11-26

Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders

Active not recruiting

656 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Smoldering Multiple Myeloma, Lymphoma, Waldenstrom Macroglobulinemia, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell

NCT02244125 2025-11-24

PCD

Phase 2 Completed

100 enrolled

Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT06304636 2025-11-24

DC15-MM-01

Phase 1 Terminated

4 enrolled

Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT07075510 2025-10-29

Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders

Phase 1/2 Recruiting

30 enrolled

Plasma cell

Neoplasms, Plasma Cell

NCT01137643 2025-10-27

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

Recruiting

15,000 enrolled

Classical hematologyDermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Pdgfra-Associated Chronic Eosinophilic Leukemia, Congenital Abnormalities, Immunoglobulin Light-chain Amyloidosis, Anemia, Aplastic, Blast Crisis, Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Leukemia, Hairy Cell, Leukemia, Mast-Cell, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Polycythemia Vera, Sezary Syndrome, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myeloid, Accelerated Phase, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Lymphoma, Extranodal NK-T-Cell, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis, Intraocular Lymphoma

NCT05336383 2025-10-09

Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma

Phase 2 Recruiting

30 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT07202052 2025-10-07

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)

Phase 2/3 Recruiting

900 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Infections, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms, Plasma Cell

NCT07202065 2025-10-07

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)

Phase 2/3 Recruiting

900 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Infections, Leukemia, Lymphoma, Neoplasms, Neoplasms, Plasma Cell

NCT07202078 2025-10-07

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)

Phase 2/3 Recruiting

900 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Infections, Leukemia, Lymphoma, Neoplasms, Neoplasms, Plasma Cell

NCT03500445 2025-10-03

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

Phase 2 Active not recruiting

75 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT07206810 2025-10-03

A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients

Completed

419 enrolled

Plasma cell

Neoplasms, Plasma Cell

NCT06487247 2025-09-17

HEME Home Transfusion Program

Phase NA Recruiting

700 enrolled

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hematologic Diseases, Leukemia, Lymphoma, Myelodysplastic Syndromes, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT04862676 2025-09-10

Repeated HBO Therapy in Myeloma Patients Undergoing High-Dose Therapy and Auto-HCT

Phase EARLY_PHASE1 Completed

29 enrolled

Plasma cell

Neoplasms, Plasma Cell

Clinical Trials

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants

REALIZE

A Study of Ninlaro in Real World Clinical Practice in China

CALySSEY

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Genome Expression in Lymphoma, Leukemia and Multiple Myeloma

Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care

Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

AI

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

DFCI 10-106

Pre-malignant States to Hematologic Malignancies in Firefighters

MMExFFPE

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

BRUOG-407

NIRVANA

HO95

Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma.

EREVA

IFM 2005-03

A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

EASE

Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma

FT576 in Subjects With Multiple Myeloma

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy

Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders

PCD

DC15-MM-01

Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients

HEME Home Transfusion Program

Repeated HBO Therapy in Myeloma Patients Undergoing High-Dose Therapy and Auto-HCT